However, at least two conditions listed as adverse events also appeared in Pfizer's 2024 list of genuine side effects. In January 2025, Snopes readers asked us about the authenticity of a long ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...

Strong performance in oncology and specialty products is fueling new growth at Pfizer. The stock's 6.3% dividend is well-funded, and management has just increased it. The bar is low for ...

Pfizer targets $4 billion in operational savings by 2024, improving margins and driving long-term profitability. PFE returned $7.1 billion via dividends in 9M-24, while reducing debt by $4.4 ...

Pfizer has abandoned development of a hemophilia A gene therapy it licensed from Sangamo Therapeutics, a move that could imperil Sangamo’s future. It’s a sudden turnabout for Pfizer, which had ...

Pfizer decided to terminate the global collaboration and license agreement between the parties. Sangamo intends to explore all options to advance the program, including seeking a potential new ...

Sangamo Therapeutics (NASDAQ:SGMO) lost nearly half of its market cap in early trading on Tuesday after Pfizer (NYSE:PFE) decided to end a collaboration with the company for its gene therapy ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...

In 1996, a pharmaceutical giant, Pfizer, administered a drug known as Trovan to children in Kano State, leading to deaths and permanent disability. Twenty-eight years after the incident ...

Notable medicines subject to price increases include Pfizer’s COVID-19 drug Paxlovid, Bristol Myers Squibb’s CAR-T therapies Abecma and Breyanzi and a clutch of vaccines from Sanofi ...

Pfizer’s research partnership with Sangamo Therapeutics produced a hemophilia A gene therapy that reached FDA discussions about a regulatory submission. That’s as far as the alliance will go.

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...